CME Activities

CLICK ON STATES TO SEE ACTIVITIES

 

Apr
2
Thu
Grand Round @ NYC Health + Hospitals/ Queens Cancer Center
Apr 2 @ 3:00 pm – 4:00 pm

4/2/2020
3-4pm

Venue
NYC Health + Hospitals/ Queens Cancer Center
Jamaica, NY

Speaker
Monica Fornier, MD

Registration

Apr
21
Tue
Grand Round @ Nashoba Valley Medical Center
Apr 21 @ 12:00 pm – 1:00 pm

4/21/2020
12-1pm

Venue
Nashoba Valley Medical Center
Ayer, MA

Speaker
Erica L. Mayer, MD, MPH

Registration

Apr
28
Tue
Grand Round @ Nassau University Medical Center
Apr 28 @ 12:00 pm – 1:00 pm

4/28/2020
12-1pm

Venue
Nassau University Medical Center
East Meadow, NY

Speaker
Adam M. Brufsky, MD, PhD

Registration

May
1
Fri
Grand Round @ SUNY Downstate Medical Center
May 1 @ 8:00 am – 9:00 am

5/1/2020
8-9am

Venue
SUNY Downstate Medical Center
Brooklyn, NY

Speaker
Sramila Aithal, MD

Registration

May
6
Wed
Grand Round @ Tidelands Health Oncology
May 6 @ 7:30 am – 8:30 am

5/6/2020
7:30 – 8:30 AM

Venue
Tidelands Health Oncology
Murrells Inlet, SC

Speaker
Shayma Master Kazmi, MD, RPh

Registration

May
13
Wed
Grand Round @ Medstar Washington Hospital Center
May 13 @ 8:00 am – 9:00 am

5/13/2020
8-9am

Venue
Medstar Washington Hospital Center
Washington, DC

Speaker
Peter A. Kaufman, MD

Registration

May
20
Wed
Grand Round @ Bay Pines VAMC
May 20 @ 12:00 pm – 1:00 pm

5/20/2020
12-1pm

Venue
Bay Pines VAMC
Bay Pines, FL

Speaker
Reshma Lillaney Mahtani, DO

Registration

Jun
3
Wed
Grand Round @ Hoboken University Medical Center
Jun 3 @ 12:00 pm – 1:00 pm

6/3/2020
12-1pm

Venue
Hoboken University Medical Center
Hoboken, NJ

Speaker
Peter A. Kaufman

Registration

 

Mar
11
Mon
The New Backbone of Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer – Animated Whiteboard View
Mar 11 2019 @ 12:00 am – Mar 11 2020 @ 12:00 am

The New Backbone of Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer – Animated Whiteboard View

PROGRAM CHAIRS

Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Texas Oncology
US Oncology Network
Dallas, TX

PROGRAM OVERVIEW

This enduring activity is focused on the care of patients with hormone receptor-positive, HER2-negative breast cancer.

TARGET AUDIENCE

This CME initiative is designed to meet the educational needs of medical oncologists, nurse practitioners, nurses, pharmacists, and other healthcare providers involved in the treatment of patients with hormone receptor-positive, HER2-negative advanced breast cancer.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Describe the involvement of CDKs and cyclins in the uncontrolled cellular proliferation characteristic of breast cancer
  • Review how to use patient and disease characteristics to identify the individual with advanced, HR+ breast cancer who would benefit from the use of CDK 4/6 inhibition
  • Analyze the properties of CDK 4/6 inhibitors and the potential pharmacodynamic effects in patients
    with hormone receptor positive, HER2-negative advanced breast cancer
  • Discuss the application of CDK 4/6 inhibitor clinical trial data to the management of breast cancer
    patients in a community oncology practice
  • Explain the patient’s and healthcare team’s responsibilities that will foster a multidisciplinary effort to
    optimize outcomes

ACCREDITATION AND DESIGNATION STATEMENTS

Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit(s) TM . Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

Nursing Credit Information 
Purpose: This program would be beneficial for nurses involved in the care of patients with breast cancer. Credits: 1.0 ANCC Contact Hour(s)

CNE Accreditation Statement 
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hours of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. O’Shaughnessy is a consultant for AstraZenea, Novartis, Pfizer, Lilly, and Celgene.

CME Content Review
The content of this activity was independently peer reviewed.

The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.

The reviewer of this activity has nothing to disclose

Staff, Planners and Managers
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the online activity.
3. Submit the evaluation form to Med Learning Group.

Participants will receive their certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/

RELEASE DATE: March 11, 2019

EXPIRATION DATE: March 11, 2020

View Activity

Mar
22
Fri
EMPOWER: Using Patient and Breast Cancer Disease Characteristics to Direct Combination Therapy in the Treatment of Metastatic HR-Positive, HER2-Negative Breast Cancer
Mar 22 2019 @ 12:00 am – Mar 22 2020 @ 12:00 am

EMPOWER: Using Patient and Breast Cancer Disease Characteristics to Direct Combination Therapy in the Treatment of Metastatic HR-Positive, HER2-Negative Breast Cancer

FACULTY

Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Texas Oncology
US Oncology Network
Dallas, TX

Mohammad Jahanzeb, MD, FACP, FASCO
Professor of Clinical Medicine, Hematology-Oncology
Medical Director, USylvester Deerfield Beach
Associate Director of Community Outreach
University of Miami
Miami, FL

PROGRAM OVERVIEW

This online activity is focused on the care of patients with hormone receptor-positive, HER2-negative breast cancer.

TARGET AUDIENCE

This CME initiative is designed to meet the educational needs of medical oncologists, nurse practitioners, nurses, pharmacists, and other healthcare providers involved in the treatment of patients with hormone receptor-positive, HER2-negative advanced breast cancer.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Describe the involvement of CDKs and cyclins in the uncontrolled cellular proliferation characteristic of breast cancer
  • Review how to use patient and disease characteristics to identify the individual with advanced, HR+ breast cancer who would benefit from the use of CDK 4/6 inhibition
  • Analyze the properties of CDK 4/6 inhibitors and the potential pharmacodynamic effects in patients with hormone receptor positive, HER2-negative advanced breast cancer
  • Discuss the application of CDK 4/6 inhibitor clinical trial data to the management of breast cancer patients in a community oncology practice
  • Explain the patient’s and healthcare team’s responsibilities that will foster a multidisciplinary effort to optimize outcomes

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 2.5 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent for their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with breast cancer.
Credits: 2.5 ANCC Contact Hours

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 2.5 contact hours of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. O’Shaughnessy is a consultant for AstraZenea, Novartis, Pfizer, Lilly, and Celgene.

Dr. Jahanzeb is a consultant for Novartis, Ipsen, Roche, Genentech, and Pfizer. He conducts research for Lilly, Boehringer Ingelheim, and Callisto.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Nina Oshiokpekhai MS PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the online activity.
3. Complete the evaluation form.

You will receive your certificate as a downloadable file after the activity.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/

RELEASE DATE: March 22, 2019

EXPIRATION DATE: March 22, 2020

View Activity

Mar
27
Wed
Nursing EMPOWER: Personalizing Patient Management through Communication and Education on Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer
Mar 27 2019 @ 12:00 am – Mar 27 2020 @ 12:00 am

Nursing EMPOWER: Personalizing Patient Management through Communication and Education on Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer

FACULTY

Shayma Master Kazmi, MD, RPh
Medical Lead of Advanced Oncology, Oncology/Hematology
Comprehensive Care and Research Center
Philadelphia, PA

PROGRAM OVERVIEW

This online activity is focused on the care of patients with early HR positive, HER2-negative breast cancer.

TARGET AUDIENCE

This CME initiative is designed to meet the educational needs of oncology nurses, nurse practitioners, and other healthcare providers involved in the treatment of patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Describe the unique mechanism of action that CDK 4/6 inhibition provides as oral oncolytic agents in advanced or metastatic HR+/HER2-negative breast cancer
  • Review the role of oral CDK 4/6 inhibitors in the treatment of advanced or metastatic breast cancer
  • Explore the side-effect profiles of the CDK 4/6 inhibitors and toxicity management in the management of advanced or metastatic HR+/HER2-negative breast cancer
  • Review the oncology nurse’s role in the recognition of breast cancer treatment-related adverse events while optimizing patient medication persistence
  • Assess ways in which to communicate more openly with patients in order to encourage their engagement across all aspects of their care
  • Evaluate current data for decision aids and shared decision-making in optimizing patient and healthcare-team communication and goal-setting

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.5 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with breast cancer. Credits: 1.5 ANCC Contact Hours

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Kazmi is a Speakers Bureau member for Merck, Eisai, Takeda, and Lilly. She is also a consultant for Eisai and Takeda.

CME CONTENT REVIEW

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE CONTENT REVIEW

The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit
participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the online activity.
3. Submit the evaluation form to Med Learning Group.

You will receive your certification via email within 30 days.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/

RELEASE DATE: March 27, 2019

EXPIRATION DATE: March 27, 2020

 

View Activity

May
15
Wed
EMPOWER: Using Patient and Breast Cancer Disease Characteristics to Direct Combination Therapy in the Treatment of Metastatic HR-Positive, HER2-Negative Breast Cancer
May 15 2019 @ 12:00 am – May 15 2020 @ 12:00 am

EMPOWER: Using Patient and Breast Cancer Disease Characteristics to Direct Combination Therapy in the Treatment of Metastatic HR-Positive, HER2-Negative Breast Cancer

VIEW ACTIVITY

PROGRAM CHAIR
Sara Hurvitz, MD
Associate Professor of Medicine
David Geffen School of Medicine at UCLA
Director, Breast Cancer Clinical Research Program
Co- Director, Santa Monica – UCLA Outpatient Oncology Practice
Santa Monica, CA

FACULTY
Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Texas Oncology
US Oncology Network
Dallas, TX

PROGRAM OVERVIEW
This online activity is focused on the care of patients with early HR-Positive, HER2-Negative Breast Cancer.

TARGET AUDIENCE
This CME initiative is designed to meet the educational needs of medical oncologists, nurse practitioners, nurses, pharmacists, and other healthcare providers involved in the treatment of patients with hormone receptor-positive, HER2-negative advanced breast cancer.

LEARNING OBJECTIVES
After completing the CME activity, learners should be better able to:

Describe the involvement of CDKs and cyclins in the uncontrolled cellular proliferation characteristic of breast cancer
Review how to use patient and disease characteristics to identify the individual with advanced, HR+ breast cancer who would benefit from the use of CDK 4/6 inhibition
Analyze the properties of CDK 4/6 inhibitors and the potential pharmacodynamic effects in patients with hormone receptor positive, HER2-negative advanced breast cancer
Discuss the application of CDK 4/6 inhibitor clinical trial data to the management of breast cancer patients in a community oncology practice
Explain the patient’s and healthcare team’s responsibilities that will foster a multidisciplinary effort to optimize outcomes
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent for their participation in the online activity.

NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with breast cancer.
Credits: 1.0 ANCC Contact Hours

CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hours of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Hurvitz has received grants and travel support from Ambryx, Amgen, Bayer, BI Pharma, Biomarin, Cascadian, Daiichi Sankyo, Dignitana, Genentech, GSK, Lilly, Macrogenics,. Medivation, Merrimack, Novartis, OBI Pharma, Pfizer, Pieris, PUMA, Roche, and Seattle Genetics.

Dr. O’Shaughnessy is a consultant for AstraZenea, Novartis, Pfizer, Lilly, and Celgene.

CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the enduring activity.
3. Submit the evaluation form to Med Learning Group.

You will receive your certificate as a downloadable file.

DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/

RELEASE DATE: May 15, 2019

EXPIRATION DATE: May 15, 2020

VIEW ACTIVITY

Summit Meetings

 

Mar
19
Thu
The Changing Landscape of Axial Spondyloarthritis: Current and Emerging Agents for Individualized Treatment @ The Westin Peachtree Plaza
Mar 19 @ 5:30 pm – 7:30 pm

The Changing Landscape of Axial Spondyloarthritis: Current and Emerging Agents for Individualized Treatment

Feel free to pass this invitation on to your physicians, fellows, physician assistants, nurses, pharmacists, healthcare practitioners, and any other colleagues who you believe would be interested in attending this free educational program.

Thursday, March 19, 2020

5:30 – 6:00 PM: Registration/Dinner
6:00 – 7:30 PM: Scientific Session

Venue
The Westin Peachtree Plaza
210 Peachtree Street NW
Atlanta GA 30303
Meeting Room: Peachtree Plaza

FEATURES

FEATURES

– Virtual Reality headsets provided to all attendees for viewing this presentation only
– Interactive, case-based learning environment
– Create your own personalized poster
– iPads provided to enhance learning experience and enable real-time Q&A

FACULTY

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
R.J. Fasenmyer Chair of Clinical Immunology
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Athanasios Tiliakos, DO
Assistant Professor
Division of Rheumatology
Emory Clinic at Emory University Hospital
Atlanta, GA

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Examine the specific domains of AxSpA and their relationship to quality of life
  • Review current and emerging therapies used for AxSpA
  • Evaluate the IL-17/23 axis and its relationship to the pathophysiology of AxSpA
  • Compare outcomes measures used in clinical trials versus those that may be more practical for use in clinical practice

TARGET AUDIENCE

This activity is intended for rheumatologists and other healthcare professionals involved in the management of patients with axial spondyloarthritis.

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity is planned and produced in accordance with ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.5 AMA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with axial spondyloarthritis..

CNE Credits:1.5 ANCC Contact Hour(s)

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the live event at info@medlearninggroup.com

Register For Live Program

Apr
9
Thu
Summit Meeting @ Chicago Marriott at Medical District/UIC
Apr 9 @ 5:30 pm – 8:00 pm

Thursday, April 9, 2020
Time
5:30 – 6:00 PM Registration and Dinner
6:00 – 8:00 PM Meeting

Venue
Chicago Marriott at Medical District/UIC
625 S Ashland Avenue at Harrison Street
Chicago, IL, 60607
Meeting Room: Ballroom

Faculty
Sramila Aithal, MD
Ruta D. Rao, MD

Register For Live Program

Apr
15
Wed
The Changing Landscape of Axial Spondyloarthritis: Current and Emerging Agents for Individualized Treatment @ San Francisco Marriott Marquis
Apr 15 @ 5:30 pm – 7:30 pm

The Changing Landscape of Axial Spondyloarthritis: Current and Emerging Agents for Individualized Treatment

Feel free to pass this invitation on to your physicians, fellows, physician assistants, nurses, pharmacists, healthcare practitioners, and any other colleagues who you believe would be interested in attending this free educational program.

Wednesday, April 15, 2020

5:30 – 6:00 PM: Registration/Dinner
6:00 – 7:30 PM: Scientific Session

San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Meeting Room: Foothill G

FEATURES

– Virtual Reality headsets provided to all attendees for viewing this presentation only
– Interactive, case-based learning environment
– Create your own personalized poster
– iPads provided to enhance learning experience and enable real-time Q&A

FACULTY

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
R.J. Fasenmyer Chair of Clinical Immunology
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Neal S. Birnbaum, MD
Director, Division of Rheumatology
California Pacific Medical Center
San Francisco, CA

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Examine the specific domains of AxSpA and their relationship to quality of life
  • Review current and emerging therapies used for AxSpA
  • Evaluate the IL-17/23 axis and its relationship to the pathophysiology of AxSpA
  • Compare outcomes measures used in clinical trials versus those that may be more practical for use in clinical practice

TARGET AUDIENCE

This activity is intended for rheumatologists and other healthcare professionals involved in the management of patients with axial spondyloarthritis.

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity is planned and produced in accordance with ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.5 AMA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with axial spondyloarthritis..

CNE Credits:1.5 ANCC Contact Hour(s)

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the live event at info@medlearninggroup.com

Register For Live Program

Apr
18
Sat
Summit Meeting @ W Hollywood
Apr 18 @ 7:30 am – 10:00 am

Saturday, April 18, 2020
Time
7:30 AM – 8:00 AM Registration / Breakfast
8:00 AM – 10:00 AM Meeting

Venue
W Hollywood
6250 Hollywood Boulevard
Hollywood, CA 90028
Meeting room: Great Room 1, 2nd floor

Faculty
Sara Hurvitz, MD
Nick McAndrew, MD MSCE

Register For Live Program

Apr
25
Sat
Summit Meeting @ Houston Marriott Medical Center/Museum District
Apr 25 @ 7:30 am – 10:00 am

Saturday, April 25, 2020
Time
7:30 AM – 8:00 AM Registration / Breakfast
8:00 AM – 10:00 AM Meeting

Venue
Houston Marriott Medical Center/Museum District
6580 Fannin Street
Houston, TX 77030-2708
Meeting Room: Grand Ballroom Salons A-D

Faculty
Joyce O’Shaughnessy, MD
TBD

Register For Live Program

May
13
Wed
Summit Meeting
May 13 @ 5:30 pm – 8:00 pm

Wednesday, May 13, 2020
Time
5:30 – 6:00 PM Registration and Dinner
6:00 – 8:00 PM Meeting

Venue
New York, NY

Meeting Room: TBD

Faculty
Joyce O’Shaughnessy, MD
Monica Fornier, MD

Register For Live Program

May
14
Thu
Summit Meeting @ The Westin Peachtree Plaza
May 14 @ 5:30 pm – 8:00 pm

Thursday, May 14, 2020
Time
5:30 – 6:00 PM Registration and Dinner
6:00 – 8:00 PM Meeting

Venue
The Westin Peachtree Plaza
210 Peachtree Street NW
Atlanta GA 30303
Meeting Room: Peachtree Plaza

Faculty
Sramila Aithal, MD
Jane Lowe Meisel, MD

Register For Live Program

May
20
Wed
Summit Meeting @ The Westin Georgetown, Washington D.C
May 20 @ 5:30 pm – 8:00 pm

Wednesday, May 20, 2020
Time
5:30 – 6:00 PM Registration and Dinner
6:00 – 8:00 PM Meeting

Venue
The Westin Georgetown, Washington D.C
2350 M Street N.W.
Washington, DC 20037
Meeting Room: Scott Room

Faculty
Joyce O’Shaughnessy, MD
TBD

Register For Live Program